Chief Medical Officer, Chief of Transplant Hepatology, Director of the Fatty Liver Program
Internal Medicine
Adult and Pediatric Hepatology
Pharmacotherapy for Obesity – Improving Body Weight and NAFLD
2021 – A Great Year For NAFLD and NASH!
Naim Alkhouri, M.D., FAASLD, is the Chief Medical Officer (CMO), Chief of Transplant Hepatology, and Director of the Fatty Liver Program at Arizona Liver Health (ALH) in Phoenix, AZ.
Prior to joining Arizona Liver Health, Dr. Alkhouri served as the director of the Metabolic Health Center at the Texas Liver Institute and Associate Professor of Medicine and Pediatrics at the University of Texas (UT) Health in San Antonio, TX.
Dr. Alkhouri completed his Gastroenterology and Transplant Hepatology training at the renowned Cleveland Clinic in Cleveland, OH where he was also appointed Assistant Professor of Medicine and Director of the Metabolic Liver Disease Clinic at the Cleveland Clinic Digestive Disease and Surgery Institute.
Dr. Alkhouri is a key opinion leader in the field of NASH therapeutics and an advisor/ consultant to many pharmaceutical and biomarker development companies. He is Principal Investigator on several multicenter global NASH trials and a member of the AASLD NASH Special Interest Group (NASH SIG).
Dr. Alkhouri has been published in over 200 publications to include publications in the New England Journal of Medicine, Lancet, JAMA, Gastroenterology, Hepatology, and Journal of Hepatology. He presents his work at both national and international medical conferences.
Among many research awards, Dr. Alkhouri received the American College of Gastroenterology Junior Faculty Development Award to study the analysis of breath volatile organic compounds to diagnose nonalcoholic fatty liver disease.
Dr. Alkhouri’s specialty interests include nonalcoholic fatty liver disease, metabolic liver diseases, viral hepatitis, autoimmune hepatitis, alpha 1 antitrypsin deficiency, and liver transplantation.